Exagen Inc. (XGN)
XGN Stock Price Chart
Explore Exagen Inc. interactive price chart. Choose custom timeframes to analyze XGN price movements and trends.
XGN Company Profile
Discover essential business fundamentals and corporate details for Exagen Inc. (XGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
19 Sept 2019
Employees
209.00
Website
https://www.exagen.comCEO
John Aballi
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
XGN Financial Timeline
Browse a chronological timeline of Exagen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.14.
Earnings released on 29 Jul 2025
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $17.20M , beating expectations by +1.86%.
Earnings released on 5 May 2025
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $15.50M , beating expectations by +6.49%.
Earnings released on 11 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $13.66M , missing expectations by -6.26%.
Earnings released on 12 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $12.51M , missing expectations by -7.58%.
Earnings released on 5 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.36 by +55.56%, while revenue for the quarter reached $15.06M , beating expectations by +11.01%.
Earnings released on 13 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.40 by +52.50%, while revenue for the quarter reached $14.42M , beating expectations by +10.12%.
Earnings released on 18 Mar 2024
EPS came in at -$0.31 surpassing the estimated -$0.41 by +24.39%, while revenue for the quarter reached $13.77M , beating expectations by +19.07%.
Earnings released on 13 Nov 2023
EPS came in at -$0.31 surpassing the estimated -$0.50 by +38.00%, while revenue for the quarter reached $13.42M , beating expectations by +14.86%.
Earnings released on 7 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.48 by +41.67%, while revenue for the quarter reached $14.14M , beating expectations by +33.62%.
Earnings released on 15 May 2023
EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $11.23M , beating expectations by +19.47%.
Earnings released on 20 Mar 2023
EPS came in at -$0.58 surpassing the estimated -$0.71 by +18.31%, while revenue for the quarter reached $12.84M , beating expectations by +48.23%.
Earnings released on 14 Nov 2022
EPS came in at -$0.47 surpassing the estimated -$0.76 by +38.16%, while revenue for the quarter reached $14.73M , beating expectations by +62.81%.
Earnings released on 4 Aug 2022
EPS came in at -$0.78 falling short of the estimated -$0.55 by -41.82%, while revenue for the quarter reached $8.96M , missing expectations by -25.50%.
Earnings released on 11 May 2022
EPS came in at -$0.60 falling short of the estimated -$0.59 by -1.69%, while revenue for the quarter reached $10.39M , beating expectations by +3.94%.
Earnings released on 22 Mar 2022
EPS came in at -$0.42 surpassing the estimated -$0.49 by +14.29%, while revenue for the quarter reached $12.69M , beating expectations by +8.37%.
Earnings released on 10 Nov 2021
EPS came in at -$0.42 surpassing the estimated -$0.43 by +2.33%, while revenue for the quarter reached $12.25M , missing expectations by -2.27%.
Earnings released on 9 Aug 2021
EPS came in at -$0.38 surpassing the estimated -$0.50 by +24.00%, while revenue for the quarter reached $12.77M , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$0.48 falling short of the estimated -$0.46 by -4.35%, while revenue for the quarter reached $10.59M , beating expectations by +2.17%.
Earnings released on 16 Mar 2021
EPS came in at -$0.27 surpassing the estimated -$0.33 by +18.18%, while revenue for the quarter reached $12.67M .
Earnings released on 10 Nov 2020
EPS came in at -$0.34 surpassing the estimated -$0.48 by +29.17%, while revenue for the quarter reached $10.78M .
XGN Stock Performance
Access detailed XGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.